Here are 1-3 brief analogies to describe ALX Oncology (ALXO):

• Like a pre-COVID vaccine Moderna, but focused on developing cutting-edge cancer immunotherapies.
• A biotech company aiming to be for 'don't eat me' signal blocking (CD47) in cancer what Kite Pharma was for CAR-T cell therapy.

• ALX148: A CD47 blocking therapeutic currently in Phase 1b/2 clinical trials for various hematologic and solid tumor cancers.
• ALTA-002: A pre-clinical SIRPa TRAAC designed to engage the innate and adaptive immune response to cancer.

ALX Oncology (ALXO) is a clinical-stage immuno-oncology company developing therapies. As such, it does not currently have approved products for sale to individual patients or healthcare providers. Its primary "customers" or revenue sources at this stage are other companies through collaborations, partnerships, and licensing agreements for the development and potential future commercialization of its product candidates.

Major customer companies (partners and licensees):

• Merck (MRK)
• Zymeworks (ZYME)
• Tallac Therapeutics
• Selexis SA
• Crystal Bioscience, Inc.

• Selexis SA
• Crystal Bioscience, Inc.

Key Business Risks for ALX Oncology (ALXO)

1. Clinical Development and Regulatory Approval Risk

ALX Oncology's primary business success hinges on the successful development and regulatory approval of its lead product candidate, ALX148. As ALX148 is currently in Phase 1b/2 clinical trials, there is significant inherent risk that it may fail to demonstrate sufficient efficacy or safety in later-stage trials, or fail to meet regulatory endpoints for approval. The majority of drug candidates do not successfully complete the development process, and any setbacks or failures in clinical trials, or an inability to obtain regulatory approval for any of its target indications, would severely impact the company's future prospects and financial viability.

2. Product Pipeline Concentration

The company is heavily reliant on the success of a single lead therapeutic candidate, ALX148, which is being investigated for multiple cancer indications. While ALX Oncology has pre-clinical products such as ALTA-002, these are in very early stages of development and offer limited immediate diversification. Consequently, if ALX148 encounters significant challenges, experiences delays, or ultimately fails in development or commercialization, the company's pipeline would be severely diminished, and its long-term viability would be substantially jeopardized due to the lack of other advanced-stage product candidates.

• For **Acute Myeloid Leukemia (AML)**, the global treatment market was estimated at approximately USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030. Other estimates place the global market at USD 3.91 billion in 2025, growing to USD 9.79 billion by 2034. Another report indicated a global market size of USD 2.1 billion in 2023, with a projection to reach USD 5.1 billion by 2032.
• The global market for **Myelodysplastic Syndromes (MDS)** drugs was valued at USD 2.8 billion in 2023 and is estimated to grow to USD 5.5 billion by 2032. Another report suggests a global market size of USD 4.55 billion in 2024, anticipated to reach around USD 11.17 billion by 2034.
• The global **Non-Hodgkin's Lymphoma (NHL)** therapeutics market was valued at USD 9.14 billion in 2022 and is expected to grow. More recent projections estimate the global non-Hodgkin lymphoma treatment market size at USD 11.59 billion in 2025, projected to grow to USD 19.44 billion by 2034.
• For **Head and Neck Squamous Cell Carcinoma (HNSCC)**, the global market size was approximately USD 2.35 billion in 2025 and is set to exceed USD 5.46 billion by 2035. In the top 7 major markets (US, EU4, UK, and Japan), the HNSCC market reached USD 1.1 billion in 2024 and is expected to reach USD 2.7 billion by 2035. The market for recurrent HNSCC in the 7 major markets (7MM) was valued at USD 1.6 billion in 2024 and is projected to reach USD 3.8 billion by 2035.
• The total market size for **HER2-positive Gastric/Gastroesophageal Junction (GEJ) Carcinoma** in the 7MM (United States, EU4, and Japan) was approximately USD 700 million in 2024 and is projected to increase during the forecast period (2025–2034). A global market report indicates the HER2 positive gastric cancer market is projected to grow from USD 1.4 billion in 2025 to USD 1.9 billion by 2035.
• The **HER2-expressing Breast Cancer** treatment market was valued at USD 8.56 billion globally in 2024 and is projected to reach USD 18.67 billion by 2033. Another source indicates the global HER2-positive breast cancer market was valued at USD 10.93 billion in 2025, increasing to USD 11.7 billion in 2026, and is projected to reach USD 15.23 billion by 2030. In the United States, the metastatic HER2-positive breast cancer market was valued at over USD 1,600 million in 2023.

Expected Drivers of Future Revenue Growth for ALX Oncology (ALXO) Over the Next 2-3 Years

ALX Oncology Holdings Inc. (ALXO) is a clinical-stage immuno-oncology company with its future revenue growth primarily tied to the successful advancement and potential commercialization of its product candidates. Over the next 2-3 years, the key drivers of future revenue growth for ALX Oncology are expected to include:

1. Advancement and Potential Regulatory Milestones for Evorpacept (ALX148) in HER2-positive Breast Cancer: ALX Oncology's lead product candidate, evorpacept (ALX148), has shown promising clinical activity in HER2-positive breast cancer, particularly in tumors overexpressing CD47. The ongoing Phase 2 ASPEN-09 breast cancer trial, which has been expanded to enroll up to 120 patients to evaluate efficacy based on CD47 expression levels, is a critical driver. Topline data from this study is anticipated in mid-2027, with the company aiming for pivotal trial readiness by the end of 2026. Successful progression in this indication could pave the way for regulatory approvals and access to a significant market opportunity.
2. Progress of ALX2004 in EGFR-expressing Solid Tumors: The development of ALX2004, a novel EGFR-targeted antibody-drug conjugate (ADC), represents a diversification of ALX Oncology's pipeline. The Phase 1 dose-escalation trial for ALX2004 in patients with EGFR-expressing solid tumors (including non-small cell lung cancer, colorectal cancer, head and neck cancer, and esophageal squamous cell cancer) is ongoing. Safety data from the dose-escalation phase is expected in the second half of 2026, with the goal of advancing this program to a stage ready for pivotal studies by the end of 2026. Positive clinical data and subsequent advancement could establish a new potential revenue stream for the company.
3. Strategic Partnerships and Collaborations for Pipeline Candidates: ALX Oncology has demonstrated a strategy of forming collaborations, such as its agreement with Zymeworks for a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab. [cite: Background] The success of these collaborations and the potential for new partnerships for its pipeline candidates, particularly as they approach later-stage development, could result in milestone payments, licensing fees, and shared commercialization revenue as products eventually reach the market.
4. Validation and Utilization of CD47 as a Predictive Biomarker: The company's focus on identifying and enriching for CD47-high patients in its evorpacept trials is a crucial strategic element. Data from both HER2-positive gastric cancer and breast cancer studies have indicated that clinical responses to evorpacept-based therapy correlate with high tumor CD47 expression levels. This biomarker-driven approach aims to improve the efficacy and success rates of clinical trials, potentially accelerating regulatory approval and commercial adoption in targeted patient populations, thereby driving future revenue growth.

Share Issuance

• ALX Oncology completed an underwritten offering in February 2026, raising approximately $150 million in gross proceeds, with net proceeds of $140.4 million.
• This offering involved the sale of 76,979,112 shares of common stock at $1.57 per share and 18,574,120 pre-funded warrants at $1.569 per warrant.
• In January 2026, the company's board increased the shares reserved for issuance under its 2025 Inducement Equity Incentive Plan by 1,300,000, bringing the total to 2,800,000 shares, intended as inducements for new or rejoining employees.

Inbound Investments

• The $150 million equity offering in early 2026 was led by new investors RA Capital Management and TCGX, with participation from new and existing investors including 5AM Ventures, Blackstone Multi-Asset Investing, OrbiMed, and Vivo Capital.
• In February 2026, venBio Capital, a venture capital firm, made a strategic investment by acquiring nearly 3.2 million shares of ALX for $5 million.

Capital Expenditures

• Research and development (R&D) expenses, which primarily fund preclinical, clinical, and development costs for product candidates evorpacept and ALX2004, decreased to $77.0 million in 2025 from $116.4 million in 2024.
• The company's cash, cash equivalents, and investments, augmented by the February 2026 financing, are projected to be sufficient to fund operating expenses, including R&D, through the first half of 2028.